US6136310A
(en)
*
|
1991-07-25 |
2000-10-24 |
Idec Pharmaceuticals Corporation |
Recombinant anti-CD4 antibodies for human therapy
|
US6440418B1
(en)
*
|
1995-11-07 |
2002-08-27 |
Idec Pharmaceuticals Corporation |
Methods of treating autoimmune diseases with gp39-specific antibodies
|
WO1998004281A1
(en)
*
|
1996-07-26 |
1998-02-05 |
Smithkline Beecham Corpration |
Improved method of treating immune cell mediated systemic diseases
|
GB9624038D0
(en)
*
|
1996-11-19 |
1997-01-08 |
Sandoz Ltd |
Organic compounds
|
US6893636B2
(en)
*
|
1997-02-20 |
2005-05-17 |
Biogen Idec Ma Inc. |
Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
|
US7033589B1
(en)
*
|
1997-02-20 |
2006-04-25 |
Biogen Idec Ma Inc. |
γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
|
AU3044697A
(en)
*
|
1997-06-24 |
1999-01-04 |
Norman Godin |
A composition for specific immunoprotection and method for obtaining said comp osition
|
US7189400B2
(en)
|
1998-03-17 |
2007-03-13 |
Genetics Institute, Llc |
Methods of treatment with antagonists of MU-1
|
US6057128A
(en)
|
1998-03-17 |
2000-05-02 |
Genetics Institute, Inc. |
MU-1, member of the cytokine receptor family
|
US7198789B2
(en)
*
|
1998-03-17 |
2007-04-03 |
Genetics Institute, Llc |
Methods and compositions for modulating interleukin-21 receptor activity
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6737056B1
(en)
*
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
KR101077001B1
(ko)
*
|
1999-01-15 |
2011-10-26 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
US20020028178A1
(en)
*
|
2000-07-12 |
2002-03-07 |
Nabil Hanna |
Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
|
AU2001249182A1
(en)
*
|
2000-03-14 |
2001-09-24 |
Genetics Institute Inc. |
Use of rapamycin and agents that inhibit b7 activity in immunomodulation
|
AU7522401A
(en)
*
|
2000-06-06 |
2001-12-17 |
Idec Pharma Corp |
Non-agonistic antibodies to human gp39, compositions containing, and therapeuticuse thereof
|
US20030103971A1
(en)
*
|
2001-11-09 |
2003-06-05 |
Kandasamy Hariharan |
Immunoregulatory antibodies and uses thereof
|
US20020159996A1
(en)
*
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
US20070065436A1
(en)
*
|
2001-01-31 |
2007-03-22 |
Biogen Idec Inc. |
Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
|
US20030211107A1
(en)
*
|
2002-01-31 |
2003-11-13 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
AR035779A1
(es)
*
|
2001-02-06 |
2004-07-14 |
Genetics Inst Llc |
Polipeptidos de fusion derivados de glicoproteina ib alfa de plaqueta y metodos de uso de los mismos
|
US6972324B2
(en)
|
2001-05-18 |
2005-12-06 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Antibodies specific for CD44v6
|
GB2376466A
(en)
*
|
2001-06-14 |
2002-12-18 |
Mark Frewin |
TRX1 antibody
|
US7541443B2
(en)
*
|
2001-06-14 |
2009-06-02 |
Tolerrx, Inc. |
Anti-CD4 antibodies
|
JP4435563B2
(ja)
*
|
2001-07-10 |
2010-03-17 |
バイオジェン アイデック インク |
アポトーシスプロセスの阻害および細胞性能の改善
|
GB2380127A
(en)
*
|
2001-09-26 |
2003-04-02 |
Isis Innovation |
Treatment of chronic joint inflammation
|
EP1432431B1
(en)
|
2001-10-04 |
2017-05-10 |
Genetics Institute LLC |
Methods and compositions for modulating interleukin-21 activity
|
EA007905B1
(ru)
|
2001-11-16 |
2007-02-27 |
Байоджен Айдек Инк. |
Полицистронная экспрессия антител
|
US20050069549A1
(en)
|
2002-01-14 |
2005-03-31 |
William Herman |
Targeted ligands
|
US20080108560A1
(en)
*
|
2002-03-05 |
2008-05-08 |
Eli Lilly And Company |
Heterologous G-Csf Fusion Proteins
|
US20030180292A1
(en)
*
|
2002-03-14 |
2003-09-25 |
Idec Pharmaceuticals |
Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
|
US20040016010A1
(en)
*
|
2002-04-17 |
2004-01-22 |
Marion Kasaian |
IL-21 receptor knockout animal and methods of use thereof
|
AU2003233008B2
(en)
*
|
2002-04-22 |
2008-04-24 |
Recopharma Ab |
Fusion polypeptides and methods for inhibiting microbial adhesion
|
EP1517701A2
(en)
*
|
2002-04-22 |
2005-03-30 |
Recopharma AB |
Lewis y epitope-containing mucin fusion polypeptide vaccines, compositions and methods of use thereof
|
CA2483473A1
(en)
*
|
2002-04-22 |
2003-10-30 |
Absorber, Ab |
Mucin fusion polypeptide vaccines, compositions and methods of use thereof
|
CA2491320A1
(en)
|
2002-07-15 |
2004-01-22 |
Wyeth |
Methods and compositions for modulating t helper (th) cell development and function
|
JP4648001B2
(ja)
*
|
2002-08-09 |
2011-03-09 |
レコファーマ アーベー |
ムチン−免疫グロブリン融合タンパク質
|
EP1543166A4
(en)
*
|
2002-09-27 |
2009-10-28 |
Genentech Inc |
SYNERGETIC COMPOSITIONS FOR PREVENTING AND TREATING THE ACQUIRED IMMUNE WEAKNESS SYNDROME
|
EP2891666B1
(en)
*
|
2002-10-16 |
2017-06-28 |
Purdue Pharma L.P. |
Antibodies that bind cell-associated CA 125/O722P and methods of use thereof
|
KR20090088973A
(ko)
*
|
2002-10-17 |
2009-08-20 |
젠맵 에이/에스 |
Cd20에 대한 인간 모노클로날 항체
|
JP4033390B2
(ja)
*
|
2002-10-30 |
2008-01-16 |
独立行政法人科学技術振興機構 |
不死化ナチュラルキラー細胞株
|
EP1460088A1
(en)
|
2003-03-21 |
2004-09-22 |
Biotest AG |
Humanized anti-CD4 antibody with immunosuppressive properties
|
JP2007524605A
(ja)
*
|
2003-04-03 |
2007-08-30 |
ピーディーエル バイオファーマ,インコーポレイティド |
インテグリンα5β1のインヒビターおよび組織顆粒化の制御のためのそれらの使用
|
AU2004247737B2
(en)
|
2003-06-11 |
2009-04-23 |
Wyeth |
Platelet glycoprotein IB alpha variant fusion polypeptides and methods of use thereof
|
GB2406094B
(en)
*
|
2003-09-17 |
2007-06-06 |
Antisoma Plc |
Modified antibody comprising an amino acid substitution mutation which confers increased stability
|
AU2004290016A1
(en)
*
|
2003-11-07 |
2005-05-26 |
Amgen Inc. |
Monkey immunoglobulin sequences
|
US7850962B2
(en)
*
|
2004-04-20 |
2010-12-14 |
Genmab A/S |
Human monoclonal antibodies against CD20
|
AR051071A1
(es)
*
|
2004-08-05 |
2006-12-20 |
Wyeth Corp |
Antagonismo de la actividad del receptor de interleuquina-21
|
CA2589422A1
(en)
*
|
2004-10-14 |
2007-04-12 |
Recopharma Ab |
Compositions and methods for inhibiting h. pylori adhesion and infection
|
US7589182B1
(en)
|
2005-01-07 |
2009-09-15 |
Los Alamos National Security, Llc |
Anti-sulfotyrosine antibodies
|
US20060193849A1
(en)
*
|
2005-02-25 |
2006-08-31 |
Antisoma Plc |
Biological materials and uses thereof
|
ES2592271T3
(es)
|
2005-03-31 |
2016-11-29 |
Chugai Seiyaku Kabushiki Kaisha |
Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos
|
GT200600148A
(es)
*
|
2005-04-14 |
2006-11-22 |
|
Metodos para el tratamiento y la prevencion de fibrosis
|
JP2009515520A
(ja)
*
|
2005-11-10 |
2009-04-16 |
レセプター バイオロジックス, インコーポレイテッド |
肝細胞成長因子イントロン融合蛋白
|
CA2633768A1
(en)
*
|
2005-11-10 |
2007-05-18 |
Bayer Schering Pharma Aktiengesellschaft |
Reduction of restenosis
|
US7495097B2
(en)
*
|
2005-11-23 |
2009-02-24 |
Brown University |
Rhodium quinonoid catalysts
|
EP1806365A1
(en)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
|
US20070184063A1
(en)
*
|
2006-01-23 |
2007-08-09 |
Jan Holgersson |
Production of Proteins Carrying Oligomannose or Human-Like Glycans in Yeast and Methods of Use Thereof
|
US20090181041A1
(en)
*
|
2006-01-23 |
2009-07-16 |
Jan Holgersson |
Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof
|
EP2264060B1
(en)
|
2006-01-26 |
2014-04-23 |
Recopharma AB |
Compositions and methods for inhibiting viral adhesion
|
AU2007227609A1
(en)
*
|
2006-03-16 |
2007-09-27 |
Genentech, Inc. |
Methods of treating lupus using CD4 antibodies
|
US20080279848A1
(en)
*
|
2006-03-16 |
2008-11-13 |
Genentech, Inc. |
Methods of treating lupus using CD4 antibodies
|
TW200806317A
(en)
*
|
2006-03-20 |
2008-02-01 |
Wyeth Corp |
Methods for reducing protein aggregation
|
JP2009536150A
(ja)
|
2006-03-23 |
2009-10-08 |
アブソルバー, アーベー |
診断および治療適用のための異なる型の血液型抗原
|
EP4342995A3
(en)
|
2006-03-31 |
2024-05-15 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
EP4218801A3
(en)
|
2006-03-31 |
2023-08-23 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody modification method for purifying bispecific antibody
|
CA2655205A1
(en)
*
|
2006-06-12 |
2007-12-21 |
Receptor Biologix Inc. |
Pan-cell surface receptor- specific therapeutics
|
TW200817438A
(en)
*
|
2006-08-17 |
2008-04-16 |
Hoffmann La Roche |
A conjugate of an antibody against CCR5 and an antifusogenic peptide
|
US20090143288A1
(en)
*
|
2007-03-13 |
2009-06-04 |
Roche Palo Alto Llc |
Peptide-complement conjugates
|
JP5721951B2
(ja)
|
2007-03-22 |
2015-05-20 |
バイオジェン アイデック マサチューセッツ インコーポレイテッド |
抗体、抗体誘導体、および抗体断片を含む、cd154に特異的に結合する結合タンパク質ならびにその使用
|
TW200902708A
(en)
*
|
2007-04-23 |
2009-01-16 |
Wyeth Corp |
Methods of protein production using anti-senescence compounds
|
TWI570135B
(zh)
*
|
2007-04-27 |
2017-02-11 |
建南德克公司 |
高效、穩定且非免疫抑制之抗-cd4抗體
|
CL2008002092A1
(es)
*
|
2007-07-20 |
2009-05-29 |
Hoffmann La Roche |
Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
|
WO2009041643A1
(ja)
|
2007-09-26 |
2009-04-02 |
Chugai Seiyaku Kabushiki Kaisha |
Cdrのアミノ酸置換により抗体の等電点を改変する方法
|
AR068563A1
(es)
|
2007-09-26 |
2009-11-18 |
Chugai Pharmaceutical Co Ltd |
Region constante de anticuerpo mutante
|
JP2011500703A
(ja)
*
|
2007-10-16 |
2011-01-06 |
シンフォジェン アクティーゼルスカブ |
最適化されたher1及びher3多量体を含む組成物、及びそれらの使用
|
ES2585480T3
(es)
|
2007-12-05 |
2016-10-06 |
Chugai Seiyaku Kabushiki Kaisha |
Anticuerpo anti-NR10 y uso del mismo
|
CA2718184A1
(en)
*
|
2008-03-13 |
2009-10-08 |
Biotest Ag |
Agent for treating disease
|
CN102027016A
(zh)
|
2008-03-13 |
2011-04-20 |
生物测试股份公司 |
一种治疗疾病的试剂
|
CN102027018A
(zh)
|
2008-03-13 |
2011-04-20 |
生物测试股份公司 |
一种治疗疾病的试剂
|
AU2009245358A1
(en)
*
|
2008-05-09 |
2009-11-12 |
Recopharma Ab |
Compositions and methods for inhibiting shiga toxin and shiga-like toxin
|
US20090280134A1
(en)
*
|
2008-05-09 |
2009-11-12 |
Recopharma Ab |
Compositions and methods for inhibiting toxin a from clostridium difficile
|
RU2535340C2
(ru)
*
|
2008-05-23 |
2014-12-10 |
Аргос Терапьютикс, Инк. |
Новые растворимые полипептиды cd83, композиции и способы их применения
|
US20100021460A1
(en)
*
|
2008-07-15 |
2010-01-28 |
Genentech, Inc. |
Methods of Treating Autoimmune Diseases Using CD4 Antibodies
|
AU2009282413B2
(en)
|
2008-08-11 |
2014-07-17 |
Nektar Therapeutics |
Multi-arm polymeric alkanoate conjugates
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
DK2341937T3
(en)
*
|
2008-09-29 |
2015-02-09 |
Biotest Ag |
Composition for the treatment of a disease
|
JP5793080B2
(ja)
*
|
2008-10-31 |
2015-10-14 |
ワイス・エルエルシー |
セラミックヒドロキシアパタイトクロマトグラフィーを使用する酸性タンパク質の精製
|
JP5511686B2
(ja)
|
2008-12-26 |
2014-06-04 |
協和発酵キリン株式会社 |
抗cd4抗体
|
EP3674317A1
(en)
|
2009-03-19 |
2020-07-01 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
WO2010107110A1
(ja)
|
2009-03-19 |
2010-09-23 |
中外製薬株式会社 |
抗体定常領域改変体
|
FR2945538B1
(fr)
|
2009-05-12 |
2014-12-26 |
Sanofi Aventis |
Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
|
BRPI1011145A2
(pt)
|
2009-05-15 |
2016-03-15 |
Chugai Pharmaceutical Co Ltd |
anticorpo anti-axl
|
EA023179B1
(ru)
*
|
2009-08-13 |
2016-05-31 |
Круселл Холланд Б.В. |
Антитела против респираторного синцитиального вируса (pcb) и способы их применения
|
WO2011035205A2
(en)
|
2009-09-18 |
2011-03-24 |
Calmune Corporation |
Antibodies against candida, collections thereof and methods of use
|
WO2011037158A1
(ja)
|
2009-09-24 |
2011-03-31 |
中外製薬株式会社 |
抗体定常領域改変体
|
WO2011062997A2
(en)
|
2009-11-17 |
2011-05-26 |
Musc Foundation For Research Development |
Human monoclonal antibodies to human nucleolin
|
GB0920944D0
(en)
|
2009-11-30 |
2010-01-13 |
Biotest Ag |
Agents for treating disease
|
EP2543730B1
(en)
|
2010-03-04 |
2018-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
FR2958936A1
(fr)
|
2010-04-14 |
2011-10-21 |
Sanofi Aventis |
Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
|
WO2011133636A1
(en)
|
2010-04-20 |
2011-10-27 |
Cedars-Sinai Medical Center |
COMBINATION THERAPY WITH CD4 LYMPHOCYTE DEPLETION AND mTOR INHIBITORS
|
KR101896124B1
(ko)
|
2010-07-09 |
2018-09-07 |
얀센 백신스 앤드 프리벤션 비.브이. |
항-인간 호흡기 세포융합 바이러스(rsv) 항체 및 사용 방법
|
UY33578A
(es)
*
|
2010-08-31 |
2012-03-30 |
Sanofi Sa |
PÉPTIDO O COMPLEJO PEPTÍDICO QUE SE UNE A INTEGRINA a(ALFA) Y MÉTODOS Y USOS QUE IMPLICAN A LOS MISMOS
|
EP2471543A1
(en)
*
|
2010-12-02 |
2012-07-04 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Tolerance induction or immunosupression to prevent in particular Graft-versus-Host-Disease (GvHD) by short-term pre-incubation of transplanted cell suspensions, tissues or organs coated with ligands to cell surface molecules
|
US20120165272A1
(en)
|
2010-12-21 |
2012-06-28 |
Recopharma Ab |
Tear Substitutes
|
US10894087B2
(en)
|
2010-12-22 |
2021-01-19 |
Nektar Therapeutics |
Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
|
WO2012088422A1
(en)
|
2010-12-22 |
2012-06-28 |
Nektar Therapeutics |
Multi-arm polymeric prodrug conjugates of taxane-based compounds
|
CA2820781A1
(en)
|
2010-12-23 |
2012-06-28 |
Sanofi |
Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
|
EP3590965A1
(en)
|
2011-03-29 |
2020-01-08 |
Roche Glycart AG |
Antibody fc variants
|
WO2012166555A1
(en)
|
2011-05-27 |
2012-12-06 |
Nektar Therapeutics |
Water - soluble polymer - linked binding moiety and drug compounds
|
EP2771694A4
(en)
|
2011-10-26 |
2015-08-05 |
Novartis Tiergesundheit Ag |
MONOCLONAL ANTIBODIES AND METHOD FOR THEIR USE
|
CA3188124A1
(en)
*
|
2012-07-05 |
2014-01-09 |
Genentech, Inc. |
Expression and secretion system
|
WO2014009465A1
(en)
|
2012-07-13 |
2014-01-16 |
Roche Glycart Ag |
Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
|
EP2722341B1
(en)
|
2012-10-22 |
2017-12-06 |
Fountain Biopharma Inc. |
Antibodies to interleukin-6 and uses thereof
|
WO2014117035A1
(en)
|
2013-01-24 |
2014-07-31 |
Transderm, Inc. |
COMPOSITIONS FOR TRANSDERMAL DELIVERY OF mTOR INHIBITORS
|
WO2014135984A2
(en)
|
2013-03-07 |
2014-09-12 |
Recopharma Ab |
Glycosylated mucin-immunoglobulin fusion protein coated device
|
WO2014189138A1
(ja)
*
|
2013-05-23 |
2014-11-27 |
Idacセラノスティクス株式会社 |
免疫不全ウイルス感染の治療又は予防剤
|
US20160158352A1
(en)
*
|
2013-07-10 |
2016-06-09 |
The United States of America, as represented by the Secretary, Department of Health & Human Servic |
Apoptotic cell-mediated induction of antigen specific regulatory t-cells for the therapy of autoimmune diseases in animals and humans
|
AU2014325063B2
(en)
|
2013-09-27 |
2019-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide heteromultimer
|
EP3102233A4
(en)
|
2014-02-05 |
2017-11-22 |
Cedars-Sinai Medical Center |
Methods and compositions for treating cancer and infectious diseases
|
BR112017014067B1
(pt)
|
2015-02-27 |
2021-01-12 |
Chugai Seiyaku Kabushiki Kaisha |
usos de um anticorpo receptor de il-6 para no tratamento de doenças relacionadas a il-6
|
WO2016159213A1
(ja)
|
2015-04-01 |
2016-10-06 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
CN106188292B
(zh)
*
|
2015-05-05 |
2019-09-24 |
北京傲锐东源生物科技有限公司 |
抗cd4蛋白单克隆抗体及其用途
|
EP3398965A4
(en)
|
2015-12-28 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR PROMOTING THE EFFICACY OF PURIFYING A POLYPEPTIDE CONTAINING AN FC REGION
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
WO2018129364A1
(en)
|
2017-01-06 |
2018-07-12 |
Palvella Therapeutics Llc |
Anhydrous compositions of mtor inhibitors and methods of use
|
EP3354278A1
(en)
|
2017-01-31 |
2018-08-01 |
Sanofi |
Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide
|
CN108690138A
(zh)
*
|
2017-04-12 |
2018-10-23 |
鸿运华宁(杭州)生物医药有限公司 |
一种能与人cd19或cd20和人cd3结合的双特异性抗体及其应用
|
WO2018203545A1
(ja)
|
2017-05-02 |
2018-11-08 |
国立研究開発法人国立精神・神経医療研究センター |
Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法
|
WO2019160907A1
(en)
*
|
2018-02-14 |
2019-08-22 |
University Of Virginia Patent Foundation |
Regulating cd4+ t cells to treat clostridium difficile infection
|
CN116327926A
(zh)
|
2018-03-15 |
2023-06-27 |
中外制药株式会社 |
对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
|
US11000513B2
(en)
|
2018-07-02 |
2021-05-11 |
Palvella Therapeutics, Inc. |
Anhydrous compositions of mTOR inhibitors and methods of use
|
CN113248612A
(zh)
*
|
2020-02-13 |
2021-08-13 |
上海君实生物医药科技股份有限公司 |
抗pd-1抗体在治疗神经内分泌瘤中的用途
|
CN113244386A
(zh)
*
|
2020-02-13 |
2021-08-13 |
上海君实生物医药科技股份有限公司 |
抗pd-1抗体在治疗肿瘤中的用途
|
CN115197320A
(zh)
*
|
2021-04-07 |
2022-10-18 |
中美冠科生物技术(太仓)有限公司 |
新型抗cd4抗体
|
EP4381081A1
(en)
|
2021-08-04 |
2024-06-12 |
Sana Biotechnology, Inc. |
Use of cd4-targeted viral vectors
|
WO2023114949A1
(en)
|
2021-12-16 |
2023-06-22 |
Sana Biotechnology, Inc. |
Methods and systems of particle production
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023168426A1
(en)
|
2022-03-03 |
2023-09-07 |
Enosi Therapeutics Corporation |
Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
WO2024044655A1
(en)
|
2022-08-24 |
2024-02-29 |
Sana Biotechnology, Inc. |
Delivery of heterologous proteins
|
WO2024064838A1
(en)
|
2022-09-21 |
2024-03-28 |
Sana Biotechnology, Inc. |
Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
|
WO2024112867A1
(en)
|
2022-11-23 |
2024-05-30 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods of use thereof for increasing immune responses
|
WO2024119157A1
(en)
|
2022-12-02 |
2024-06-06 |
Sana Biotechnology, Inc. |
Lipid particles with cofusogens and methods of producing and using the same
|